10900 rBV A/B appears to be well tolerated and immunogenic in humans at the three dosages evaluated. Based upon information available to date, advancement of rBV A/B to Phase 2 testing for schedule selection appears warranted. false 1819 recombinant, vaccine, BoNT, botulinum, neurotoxin, neutralization, rBV A/B en false true false initial_evaluation_of_a_recombinant_clostridium_botulinum_a_b_vaccine_rbv_a_b_in_healthy_volunteers active Initial Evaluation of a Recombinant Clostridium botulinum A/B Vaccine (rBV A/B) in Healthy Volunteers